2. Search Result
Search Result
Results for "

adenylate cyclase inhibitor

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

4

Biochemical Assay Reagents

4

Peptides

2

Inhibitory Antibodies

2

Natural
Products

2

Isotope-Labeled Compounds

8

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W010918
    Adenosine 5'-diphosphate
    5+ Cited Publications

    Adenosine diphosphate; ADP

    		 Endogenous Metabolite Others
    Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors.
    Adenosine 5'-diphosphate
  • HY-100396
    SQ22536
    Maximum Cited Publications
    39 Publications Verification

    		 Adenylate Cyclase Metabolic Disease
    SQ22536 is an effective adenylate cyclase (AC) inhibitor.
    SQ22536
  • HY-103193
    NKH477

    Colforsin dapropate hydrochloride

    		 Adenylate Cyclase Cardiovascular Disease
    NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of adenylate cyclase and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function. NKH477 exerts an antiproliferative effect in vivo with an altered cytokine profile to inhibit the acute rejection of rat orthotopic lung allografts .
    NKH477
  • HY-Y1092
    N,N-Dicyclohexylcarbodiimide(DCC)
    2 Publications Verification

    		 Biochemical Assay Reagents Adenylate Cyclase Others
    N,N-Dicyclohexylcarbodiimide(DCC) is a dehydrating and condensing agent. N,N-Dicyclohexylcarbodiimide(DCC) enhances adenylate cyclase activity. N,N-Dicyclohexylcarbodiimide(DCC) inhibits amine accumulation. N,N-Dicyclohexylcarbodiimide(DCC) is used to prepare 3-phenylcoumarin derivatives, sulfated derivatives of purslane polysaccharides .
    N,N-Dicyclohexylcarbodiimide(DCC)
  • HY-W010791
    Adenosine 5'-diphosphate sodium salt
    5+ Cited Publications

    		 Endogenous Metabolite Others
    Adenosine 5'-diphosphate sodium salt is a nucleoside diphosphate and the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate sodium salt induces human platelet aggregation and inhibits stimulated adenylate cyclase through its action on P2T-purinergic receptors .
    Adenosine 5'-diphosphate sodium salt
  • HY-147557
    PA-915
    1 Publications Verification

    PAC1R antagonist 1

    		 PACAP Receptor Neurological Disease
    PA-915 (PAC1R antagonist 1) is a potent and orally active antagonist of PAC1 receptor. PA-915 inhibits pituitary adenylate cyclase-activating polypeptide (PACAP)-induced CREB phosphorylation. PA-915 can inhibit PACAP- and nerve injury-induced allodynia. PA-915 can be used for the research of neuropathic pain .
    PA-915
  • HY-P3617
    Glucagon (22-29)

    		GCGR Metabolic Disease
    Glucagon (22-29) is partial agonist of Glucagon (19–29). Glucagon specifically inhibits the Ca 2+ pump in liver plasma membranes independently of adenylate cyclase activation .
    Glucagon (22-29)
  • HY-103185
    CCPA
    1 Publications Verification

    2-Chloro-N6-cyclopentyladenosine

    		 Adenosine Receptor Adenylate Cyclase Cardiovascular Disease Neurological Disease
    CCPA (2-Chloro-N6-cyclopentyladenosine) a highly selective A1 adenosine receptors agonist with a Ki of 0.4 nM. CCPA inhibits adenylate cyclase with an IC50 of 33 nM. CCPA exhibits anti-seizure and cardiacprotective activity. CCPA can be used for the research of seizure and myocardial infarction .
    CCPA
  • HY-116530
    9-Cyclopentyladenine monomethanesulfonate

    9-CP-Ade mesylate

    		 Adenylate Cyclase Others Neurological Disease
    9-Cyclopentyladenine monomethylsulfonate (9-CP-Ade mesylate) is a stable non-competitive adenylate cyclase inhibitor with cell permeable properties .
    9-Cyclopentyladenine monomethanesulfonate
  • HY-135490
    Reproterol

    		Adrenergic Receptor Phosphodiesterase (PDE) Inflammation/Immunology
    Reproterol is a selective β2-adrenoceptor agonist and cAMP phosphodiesterase (PDE) inhibitor. Reproterol inhibits adenylate cyclase-induced phosphodiesterase activity. Reproterol inhibits histamine release from mast cells. Reproterol is applicable to research related to asthma .
    Reproterol
  • HY-W250153
    Adenosine 3'-phosphate 5'-phosphosulfate lithium

    		P2Y Receptor Cardiovascular Disease
    Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
    Adenosine 3'-phosphate 5'-phosphosulfate lithium
  • HY-101862
    CB-7921220

    		Adenylate Cyclase Cardiovascular Disease Neurological Disease
    CB-7921220 is an adenylate cyclase inhibitor.
    CB-7921220
  • HY-W010918S2
    Adenosine 5'-diphosphate-15N5 dilithium

    Adenosine diphosphate-15N5 dilithium; ADP-15N5 dilithium

    		 Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease
    Adenosine 5'-diphosphate- 15N5 (Adenosine diphosphate- 15N5 dilithium) dilithium is 15N labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors.
    Adenosine 5'-diphosphate-15N5 dilithium
  • HY-164090
    Adenosine 3'-phosphate 5'-phosphosulfate

    		P2Y Receptor Cardiovascular Disease
    Adenosine 3'-phosphate 5'-phosphosulfate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
    Adenosine 3'-phosphate 5'-phosphosulfate
  • HY-129421
    PA-9

    		PACAP Receptor Neurological Disease Inflammation/Immunology
    PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC50 of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain .
    PA-9
  • HY-W010918S3
    Adenosine 5'-diphosphate-13C5

    Adenosine diphosphate-13C5; ADP-13C5

    		 Isotope-Labeled Compounds Endogenous Metabolite Others
    Adenosine 5'-diphosphate- 13C5 (Adenosine diphosphate- 13C5) is the 13C-labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors.
    Adenosine 5'-diphosphate-13C5
  • HY-W010918R
    Adenosine 5'-diphosphate (Standard)

    Adenosine diphosphate (Standard); ADP (Standard)

    		 Reference Standards Endogenous Metabolite Others
    Adenosine 5'-diphosphate (Standard) is the analytical standard of Adenosine 5'-diphosphate. This product is intended for research and analytical applications. Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors. In Vitro: Adenosine 5'-diphosphate consists of the pyrophosphate group, the pentose sugar ribose, and the nucleobase adenine. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. ADP is converted back to ATP by ATP synthases. ATP is an important energy transfer molecule in cells. Adenosine 5'-diphosphate is utilized in a wide number of cellular processes, including respiration, biosynthetic reactions, motility, and cell division.
    Adenosine 5'-diphosphate (Standard)
  • HY-122357
    Bestim

    γ-Glu-Trp

    		 Adenylate Cyclase Inflammation/Immunology
    Bestim (γ-Glu-Trp) is a dipeptide, which exhibits high affinity to murine peritoneal macrophages, thymocytes, and plasma membranes isolated from these cells, with Kds of 3.1, 2.1, 18.6 and 16.7 nM, respectively. Bestim inhibits adenylate cyclase in the membranes of murine macrophages and thymocytes. Bestim exhibits immunomodulatory efficacy .
    Bestim
  • HY-Y1092R
    N,N-Dicyclohexylcarbodiimide(DCC) (Standard)

    		Biochemical Assay Reagents Reference Standards Others
    N,N-Dicyclohexylcarbodiimide(DCC) (Standard) is the analytical standard of N,N-Dicyclohexylcarbodiimide(DCC). This product is intended for research and analytical applications. N,N-Dicyclohexylcarbodiimide(DCC) is a dehydrating and condensing agent. N,N-Dicyclohexylcarbodiimide(DCC) enhances adenylate cyclase activity. N,N-Dicyclohexylcarbodiimide(DCC) inhibits amine accumulation. N,N-Dicyclohexylcarbodiimide(DCC) is used to prepare 3-phenylcoumarin derivatives, sulfated derivatives of purslane polysaccharides .
    N,N-Dicyclohexylcarbodiimide(DCC) (Standard)
  • HY-401913
    endo CNTinh-03

    		Phosphodiesterase (PDE) Infection Cancer
    Endo CNTinh-03 is inhibitor for the elevation of cAMP and cGMP induced by agonist, such as G protein-coupled receptors, adenylate cyclase, and guanylate cyclase (IC50 is 4 μM). Endo CNTinh-03 inhibits cholera toxin- and Escherichia coli (STa) toxin- induced CFTR chloride current, ameliorates secretory diarrhea in mouse models, and prevents cyst growth in polycystic kidney disease model .
    endo CNTinh-03
  • HY-P2090A
    Angiopeptin TFA

    		Somatostatin Receptor Adenylate Cyclase Cardiovascular Disease
    Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .
    Angiopeptin TFA
  • HY-N9422
    Adenosine 3'-phosphate 5'-phosphosulfate triethylamine

    		P2Y Receptor Cardiovascular Disease
    Adenosine 3'-phosphate 5'-phosphosulfate triethylamine, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
    Adenosine 3'-phosphate 5'-phosphosulfate triethylamine
  • HY-131789A
    2-NH2-PuTP sodium

    n2h6ATP sodium

    		 Adenylate Cyclase Metabolic Disease
    2-NH2-PuTP (n2h6ATP) sodium, an ATP (HY-B2176) analogue, is a competitive pyruvate-stimulated adenylate cyclase inhibitor with a Ki of 1.7 mM.
    2-NH2-PuTP sodium
  • HY-12132
    DMP 904

    		CRFR Adenylate Cyclase Neurological Disease
    DMP 904 is a noncompetitive full corticotropin-releasing factor receptor (CRFR) antagonist. DMP 904 can inhibit CRF-stimulated adenylate cyclase activity and ACTH release. DMP 904 exhibits anti-depressant and anti-anxiety activity .
    DMP 904
  • HY-P991123
    Bocunebart

    ALD1910; LU AG-09222

    		 Adenylate Cyclase Inflammation/Immunology
    Bocunebart is a humanized monoclonal antibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
    Bocunebart
  • HY-D0882
    Adenosine 5'-diphosphate dicyclohexylammonium

    		Biochemical Assay Reagents Cardiovascular Disease
    Adenosine 5'-diphosphate dicyclohexylammonium is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate dicyclohexylammonium induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors .
    Adenosine 5'-diphosphate dicyclohexylammonium
  • HY-122221
    KUM 32

    		Adrenergic Receptor Adenylate Cyclase Cardiovascular Disease
    KUM 32 is a potent antagonist of epinephrine-induced platelet aggregation. KUM 32 is an adenylate cyclase activity inhibitor. KUM 32 binds to the alpha 2 adrenergic receptor of human platelets .
    KUM 32
  • HY-W250153A
    Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate

    		P2Y Receptor Cardiovascular Disease
    Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
    Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate
  • HY-100396R
    SQ22536 (Standard)

    		Reference Standards Adenylate Cyclase Metabolic Disease
    SQ22536 (Standard) is the analytical standard of SQ22536. This product is intended for research and analytical applications. SQ22536 is an effective adenylate cyclase (AC) inhibitor.
    SQ22536 (Standard)
  • HY-122148
    DA 4626

    		Adenylate Cyclase Histamine Receptor Metabolic Disease
    DA 4626 is a competitive H2-histamine receptor antagonist. DA 4626 inhibits adenylate cyclase activity with a KB value of 40 nM .
    DA 4626
  • HY-118008A
    Lesopitron hydrochloride

    		5-HT Receptor Neurological Disease
    Lesopitron hydrochloride is a 5-HT receptor agonist with potent anxiolytic-like effects. Lesopitron hydrochloride inhibits forskolin-stimulated adenylate cyclase activity with an IC50 value of 125 nM .
    Lesopitron hydrochloride
  • HY-111985
    Revospirone

    BAY Vq 7813

    		 5-HT Receptor Adenylate Cyclase Others
    Revospirone (BAY Vq 7813) is a partial agonist of the 5-HT1A receptor with a Ki of 2 nmol/L. Revospirone inhibits adenylate cyclase activity with an IC50 of 124 nmol/L .
    Revospirone
  • HY-118008
    Lesopitron

    		5-HT Receptor Neurological Disease
    Lesopitron (E-4424) is a 5-HT receptor agonist with potent anxiolytic-like effects. Lesopitron inhibits forskolin-stimulated adenylate cyclase activity with an IC50 value of 125 nM .
    Lesopitron
  • HY-169263
    AC10142A

    		Adenylate Cyclase Neurological Disease Inflammation/Immunology
    AC10142A is a selective Adenylyl Cyclase Type 1 inhibitor with IC50 of 0.26 μM. AC10142A can be used to study pain models .
    AC10142A
  • HY-118086
    MRS1067

    		Adenosine Receptor Inflammation/Immunology Cancer
    MRS 1067 is a competitive antagonist of the adenosine A3 receptor that inhibits the suppression of adenylate cyclase by adenosine A3 receptor agonists and affects the activation of G proteins. MRS 1067 can be used in research related to inflammation and cancer .
    MRS1067
  • HY-157150
    mAC2-IN-1

    		Adenylate Cyclase Infection
    mAC2-IN-1 (compound 14) is a potent and selective human adenylate cyclases (mACs) inhibitor with an IC50 of 4.45 μM. mAC2-IN-1 has low activity on mAC1 and mAC5 .
    mAC2-IN-1
  • HY-112658
    p-Iodoclonidine hydrochloride

    		Adrenergic Receptor Adenosine Receptor Endocrinology
    p-Iodoclonidine hydrochloride is a partial agonist of α2-adrenergic receptor. p-Iodoclonidine hydrochloride also has minimal agonist activity in inhibiting adenylate cyclase in platelet membranes, and potentiates ADP induced platelet aggregation with an EC50 of 1.5 μM .
    p-Iodoclonidine hydrochloride
  • HY-131776A
    2-Chloro-ADP sodium

    2-Chloroadenosine 5′-diphosphate sodium

    		 Adenylate Cyclase HSP Cardiovascular Disease
    2-Chloro-ADP (2-Chloroadenosine 5′-diphosphate) sodium is a Adenosine 5'-diphosphate (ADP; HY-W010918) derivative that induces human platelet aggregation and inhibits stimulated adenylate cyclase . 2-Chloro-ADP sodium inhibits mortalin nucleotide-binding domain (NBD) with a Ki of 45.05 μM .
    2-Chloro-ADP sodium
  • HY-103185A
    CCPA hemihydrate

    2-Chloro-N6-cyclopentyladenosine hemihydrate

    		 Adenosine Receptor Adenylate Cyclase Cardiovascular Disease Neurological Disease
    CCPA (2-Chloro-N6-cyclopentyladenosine) hemihydrate a highly selective A1 adenosine receptors agonist with a Ki of 0.4 nM. CCPA hemihydrate inhibits adenylate cyclase with an IC50 of 33 nM. CCPA hemihydrate exhibits anti-seizure and cardiacprotective activity. CCPA hemihydrate can be used for the research of seizure and myocardial infarction .
    CCPA hemihydrate
  • HY-131776
    2-Chloro-ADP

    2-Chloroadenosine 5′-diphosphate

    		 Adenylate Cyclase HSP Cardiovascular Disease
    2-Chloro-ADP (2-Chloroadenosine 5′-diphosphate) sis a Adenosine 5'-diphosphate (ADP; HY-W010918) derivative that induces human platelet aggregation and inhibits stimulated adenylate cyclase . 2-Chloro-ADP inhibits mortalin nucleotide-binding domain (NBD) with a Ki of 45.05 μM .
    2-Chloro-ADP
  • HY-110070
    DL-AP4 sodium

    2-Amino-4-phosphonobutyric acid sodium

    		 mGluR Others Neurological Disease
    DL-AP4 sodium (2-Amino-4-phosphonobutyric acid sodium) is an agonist for metabotropic glutamate receptors (mGluR). DL-AP4 sodium binds to mGluR4, activates the signaling pathway that is negatively correlated with adenylate cyclase, and inhibits the Forskolin (HY-15371)-induced production of cAMP. DL-AP4 sodium is also an inhibitor for ON channel, that reduces the sensitivity of photoreceptors to brightness changes .
    DL-AP4 sodium
  • HY-P2090
    Angiopeptin

    		Somatostatin Receptor Adenylate Cyclase Cardiovascular Disease
    Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .
    Angiopeptin
  • HY-103185R
    CCPA (Standard)

    2-Chloro-N6-cyclopentyladenosine (Standard)

    		 Reference Standards Adenosine Receptor Adenylate Cyclase Cardiovascular Disease Neurological Disease
    CCPA (2-Chloro-N6-cyclopentyladenosine (Standard)) is the analytical standard of CCPA (HY-103185). This product is intended for research and analytical applications. CCPA (2-Chloro-N6-cyclopentyladenosine) a highly selective A1 adenosine receptors agonist with a Ki of 0.4 nM. CCPA inhibits adenylate cyclase with an IC50 of 33 nM. CCPA exhibits anti-seizure and cardiacprotective activity. CCPA can be used for the research of seizure and myocardial infarction .
    CCPA (Standard)
  • HY-148032
    5-Benzyloxytryptamine

    5-BT

    		 5-HT Receptor Neurological Disease
    5-Benzyloxytryptamine (5-BT) is a selective partial agonist for 5-hydroxytryptamine 1D/1B (5-HT1D/1B) receptors with an IC50 value of 40 nM for bovine caudate 5-HT1D and reduced affinity for other receptors (5-HT2 IC50>470 nM). 5-Benzyloxytryptamine inhibits adenylate cyclase to decrease neurotransmitter release and downregulate cAMP signaling. 5-Benzyloxytryptamine is promising for research of neurotransmitter imbalance-related disorders like migraine .
    5-Benzyloxytryptamine
  • HY-179376
    Anti-virulence factor-IN-3

    		Bacterial Infection
    Anti-virulence factor-IN-3 (Compound 21) is a covalent β-aminosulfinyl type anthrax edema factor (EF) inhibitor, with a Ki value of 0.44 μM. Anti-virulence factor-IN-3 generates an active ethylene sulfinyl intermediate, which forms an irreversible covalent bond with the Lys residue at the active center of EF, permanently inhibiting the adenylate cyclase activity of EF. Anti-virulence factor-IN-3 effectively inhibits the cAMP production induced by EF, with an EC50 value of 0.15 μM. Anti-virulence factor-IN-3 can be used for research on anthrax Infection .
    Anti-virulence factor-IN-3
  • HY-185668
    2',5'-Dideoxy-3'-ATP

    		Adenylate Cyclase Others
    2',5'-Dideoxy-3'-ATP is an adenylate cyclase inhibitor. 2',5'-Dideoxy-3'-ATP exerts linear noncompetitive inhibition via binding to the distinct P-site. 2',5'-Dideoxy-3'-ATP binds and stabilizes the dimeric form of Mycobacterium avium adenylyl cyclase Ma1120 to inhibit activity .
    2',5'-Dideoxy-3'-ATP
  • HY-103193R
    NKH477 (Standard)

    Colforsin dapropate hydrochloride (Standard)

    		 Reference Standards Adenylate Cyclase Cardiovascular Disease
    NKH477 (Standard) is the analytical standard of NKH477 (HY-103193). This product is intended for research and analytical applications. NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of adenylate cyclase and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function. NKH477 exerts an antiproliferative effect in vivo with an altered cytokine profile to inhibit the acute rejection of rat orthotopic lung allografts .
    NKH477 (Standard)
  • HY-147129
    cGAS-IN-9

    		Guanylate Cyclase Adenylate Cyclase CXCR NF-κB Inflammation/Immunology
    cGAS-IN-9 is a cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) inhibitor, with IC50 values of 27.5 nM and 5.15 μM against human and murine cGAS, respectively. cGAS-IN-9 shows weak inhibitory activity against human soluble adenylate cyclase, with an IC50 of 26.4 μM. cGAS-IN-9 inhibits dsDNA-induced expression of IFNB1 and CXCL10, as well as activation of the NF-κB pathway, in human immune cells. cGAS-IN-9 can be used in research related to cGAS-dependent inflammatory diseases .
    cGAS-IN-9
  • HY-P991964
    Rendomab B4

    Rendomab-B49

    		 Endothelin Receptor Cancer
    Rendomab B4 (Rendomab-B49) is a monoclonal antibody targeting ETB. Rendomab B4 preferentially binds to ETB in the active conformational state and exhibits selectivity for ETB on melanoma cells. Rendomab B4 inhibits the G protein-dependent phospholipase C (PLC) pathway, blocks ET-3-induced Gαi/o-mediated inhibition of adenylate cyclase, and does not affect the activation of the ERK1/2 pathway. Rendomab B4 is applicable to melanoma-related research .
    Rendomab B4
  • HY-W686762
    m,p-Dimethyl PPE

    		Dopamine Receptor Adenylate Cyclase Neurological Disease
    m,p-Dimethyl PPE is a D4 dopamine receptor ligand. m,p-Dimethyl PPE promotes GDP/GTP exchange of the G protein α-subunit, dissociates the receptor-G protein complex, stabilizes the low-affinity receptor state, and inhibits adenylate cyclase activity. m,p-Dimethyl PPE inhibits Forskolin (HY-15371)-induced melatonin synthesis in retinal photoreceptor cells and reduces the efficacy of full agonists when used in combination. m,p-Dimethyl PPE can be used in studies related to attention-deficit hyperactivity disorder .
    m,p-Dimethyl PPE

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: